<DOC>
	<DOCNO>NCT02421172</DOCNO>
	<brief_summary>This randomize , double blind , multicenter study patient moderate severe chronic hidradenitis suppurativa parallel group , determine efficacy safety multiple dos CJM112 comparison placebo . The study two period explore preliminary dose effect .</brief_summary>
	<brief_title>Efficacy , Safety , Pharmacokinetics Study CJM112 Hidradenitis Suppurativa Patients</brief_title>
	<detailed_description />
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<criteria>1 . Male female patient 18 65 year age clinically diagnose chronic HS least 1 year ( prior screening ) undergone previous antibiotic therapy 2 . Weight 50 kg 150 kg 3 . HSPGA score least moderate severity time inclusion least 4 abscess and/or nodule . HS lesion must present least two distinct anatomical area , least one area must minimally Hurley Stage II ( moderate ) 1 . Use previous biologics specify concomitant medication 2 . Use systemic treatment HS last 4 week prior randomization 3 . Presence 25 drain fistula . 4 . Surgical treatment HS last 4 week prior randomization/first treatment . 5 . Women childbearing potential sexually active male unwilling use condom intercourse take drug 15 week stop investigational medication . 6 . Evidence active tuberculosis screen 7 . History severe systemic Candida infection evidence Candidiasis last two week 8 . Active systemic skin infection ( common cold HS relate ) two week randomization/first treatment 9 . Any live vaccine ( include nasal spray flu vaccine ) start 6 week randomization . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hidradenitis Suppurativa</keyword>
</DOC>